Last reviewed · How we verify
MET + Vildagliptin Group
This combination uses metformin to reduce hepatic glucose production and improve insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.
This combination therapy uses metformin to reduce hepatic glucose production and improve insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | MET + Vildagliptin Group |
|---|---|
| Also known as | Galvus®, Glyburide, Glucophage |
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Drug class | Combination antidiabetic agent (biguanide + DPP-4 inhibitor) |
| Target | Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon secretion. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Hypoglycemia
- Headache
- Nasopharyngitis
Key clinical trials
- Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes (PHASE4)
- Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MET + Vildagliptin Group CI brief — competitive landscape report
- MET + Vildagliptin Group updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI